Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 475
Filter
1.
Biomed Pharmacother ; 144: 112253, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34607106

ABSTRACT

Iron supplementation is necessary for the treatment of anemia, one of the most frequent complications in inflammatory bowel disease (IBD). However, oral iron supplementation leads to an exacerbation of intestinal inflammation. Gut barrier plays a key role in the pathogenesis of IBD. The aim of this study was to characterize the interrelationship between systemic iron, intestinal barrier and the development of intestinal inflammation in a dextran sulfate sodium (DSS) induced experimental colitis mice model. We found that DSS-treated mice developed severe inflammation of colon, but became much healthy when intraperitoneal injection with iron. Iron supplementation alleviated colonic and systemic inflammation by lower histological scores, restorative morphology of colonic villi, and reduced expression of pro-inflammatory cytokines. Moreover, intraperitoneal supplementation of iron enhanced intestinal barrier function by upregulating the colonic expressions of tight junction proteins, restoring intestinal immune homeostasis by regulating immune cell infiltration and T lymphocyte subsets, and increasing mucous secretion of goblet cells in the colon. High-throughput sequencing of fecal 16 S rRNA showed that iron injection significantly increased the relative abundance of Bacteroidetes, which was suppressed in the gut microbiota of DSS-induced colitis mice. These results provided evidences supporting the protective effects of systemic iron repletion by intraperitoneal injection of iron on intestinal barrier functions. The finding highlights a novel approach for the treatment of IBD with iron injection therapy.


Subject(s)
Colitis/drug therapy , Colon/drug effects , Dietary Supplements , Goblet Cells/drug effects , Intestinal Mucosa/drug effects , Iron-Dextran Complex/administration & dosage , Tight Junction Proteins/metabolism , Animals , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/metabolism , Colitis/chemically induced , Colitis/metabolism , Colitis/microbiology , Colon/metabolism , Colon/microbiology , Dextran Sulfate , Disease Models, Animal , Dysbiosis , Gastrointestinal Microbiome/drug effects , Goblet Cells/metabolism , Goblet Cells/microbiology , Injections, Intraperitoneal , Intestinal Mucosa/metabolism , Intestinal Mucosa/microbiology , Male , Mice, Inbred C57BL , Permeability , Tight Junctions/drug effects , Tight Junctions/metabolism , Tight Junctions/microbiology , Up-Regulation
2.
Am J Hematol ; 95(12): 1572-1577, 2020 12.
Article in English | MEDLINE | ID: mdl-32918335

ABSTRACT

There are multiple intravenous (IV) iron formulations available, of which several may be administered as single-dose infusions such as low-molecular weight iron dextran (LMWID), ferumoxytol, ferric carboxymaltose, and ferric derisomaltose. However, administration of ferumoxytol as a single-dose infusion is off-label as it is approved as a two-dose series. Previous studies of ferumoxytol alone support the effectiveness and safety of the single-dose regimen, but there is a paucity of data directly comparing single-dose ferumoxytol to other single-dose IV iron formulations. This multicenter cohort study sought to affirm the safety and effectiveness of single-dose ferumoxytol compared to single-dose LMWID. Overall, 906 patients who received single-dose LMWID (n = 439) or ferumoxytol (n = 467) were identified, of whom 351 met criteria for the primary effectiveness endpoint defined as median change in hemoglobin (Hb), hematocrit (Hct), and ferritin 8 to 12 weeks from baseline. All 906 patients were included for the secondary analysis evaluating the incidence of adverse events (AE) and requirement of additional IV iron infusions. Median change in Hb (LMWID 0.5 g/dL; ferumoxytol 0.8 g/dL; P = .24), Hct (LMWID 1.1%; ferumoxytol 1.25%; P = .89), and ferritin (LMWID 87 ng/dL; ferumoxytol 71 ng/dL; P = .47) was not significantly different between groups. Both groups experienced similar rates of AEs (LMWID 2.3%; ferumoxytol 2.8%; P = .63). The LMWID patients more frequently required additional IV iron infusions (LMWID 28.5%; ferumoxtyol 16.1%; P < .001). These findings support that single-dose ferumoxytol is effective and safe, and that patients may require fewer additional infusions compared to patients who received LMWID.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Ferrosoferric Oxide/administration & dosage , Iron Deficiencies , Iron-Dextran Complex/administration & dosage , Adult , Aged , Anemia, Iron-Deficiency/blood , Female , Ferrosoferric Oxide/adverse effects , Hematocrit , Hemoglobins/metabolism , Humans , Iron/blood , Iron-Dextran Complex/adverse effects , Male , Middle Aged
3.
J Anim Sci ; 98(8)2020 Aug 01.
Article in English | MEDLINE | ID: mdl-32663303

ABSTRACT

A total of 336 newborn pigs (DNA 241 × 600, initially 1.75 ± 0.05 kg bodyweight [BW]) from 28 litters were used in a 63-d study evaluating the effects of increasing injectable Fe dose on suckling and subsequent nursery pig performance and blood Fe status. GleptoForte (Ceva Animal Health, LLC, Lenexa, KS) contains gleptoferron which is an Fe macromolecule complex that is commercially used as an injectable Fe source for suckling piglets. On the day of processing (day 3 after birth), all piglets were weighed and 6 barrows and 6 gilts per litter were allotted within sex to 1 of 6 treatments in a completely randomized design. Treatments consisted of a negative control receiving no Fe injection and increasing injectable Fe to achieve either 50, 100, 150, 200 mg, or 200 mg plus a 100 mg injection on day 11 after birth. Pigs were weaned (~21 d of age) and allotted to nursery pens based on BW and corresponding treatment in a completely randomized design. During lactation, increasing injectable Fe up to 100 mg improved (quadratic; P < 0.05) average daily gain (ADG) and day 21 BW with no further improvement thereafter. There was no evidence of differences (P > 0.10) observed between the 200 mg and 200 mg + 100 mg treatments for growth. For the nursery period, increasing Fe dosage increased (linear; P < 0.05) ADG, average daily feed intake, and day 42 BW. There was no evidence of differences (P > 0.10) between the 200 mg and 200 mg + 100 mg treatments for nursery growth. For blood criteria, significant treatment × day interactions (P = 0.001) were observed for hemoglobin (Hb) and hematocrit (Hct). The interactions occurred because pigs that had <150 mg of injectable Fe had decreased values to day 21 and then increased to day 63 while pigs with 150 or 200 mg of injectable Fe had increased values to day 21 then stayed relatively constant to day 63. In summary, piglet performance during lactation was maximized at 100 mg while nursery growth performance and blood Fe status were maximized with a 200 mg Fe injection at processing. Providing an additional 100 mg of Fe on day 11 of age increased Hb, and Hct values at weaning and 14 d into the nursery but did not provide a growth performance benefit in lactation or nursery. These results indicate that providing 200 mg of injectable Fe provided from GleptoForte is sufficient to optimize lactation and subsequent nursery growth performance and blood Fe status.


Subject(s)
Iron-Dextran Complex/administration & dosage , Iron/administration & dosage , Sugar Acids/administration & dosage , Swine/growth & development , Animals , Animals, Newborn , Body Weight , Diet , Dose-Response Relationship, Drug , Drug Combinations , Female , Hematocrit/veterinary , Male , Swine Diseases
4.
Blood Cells Mol Dis ; 83: 102440, 2020 07.
Article in English | MEDLINE | ID: mdl-32353700

ABSTRACT

Patients with blood transfusion-dependent anemias develop transfusional iron overload (TIO), which may cause cardiosiderosis. In patients with an ineffective erythropoiesis, such as thalassemia major, common transfusion regimes aim at suppression of erythropoiesis and of enteral iron loading. Recent data suggest that maintaining residual, ineffective erythropoiesis may protect from cardiosiderosis. We investigated the common consequences of TIO, including cardiosiderosis, in a minipig model of iron overload with normal erythropoiesis. TIO was mimicked by long-term, weekly iron-dextran injections. Iron-dextran loading for around one year induced very high liver iron concentrations, but extrahepatic iron loading, and iron-induced toxicities were mild and did not include fibrosis. Iron deposits were primarily in reticuloendothelial cells, and parenchymal cardiac iron loading was mild. Compared to non-thalassemic patients with TIO, comparable cardiosiderosis in minipigs required about 4-fold greater body iron loads. It is suggested that this resistance against extrahepatic iron loading and toxicity in minipigs may at least in part be explained by a protective effect of the normal erythropoiesis, and additionally by a larger total iron storage capacity of RES than in patients with TIO. Parenteral iron-dextran loading of minipigs is a promising and feasible large-animal model of iron overload, that may mimic TIO in non-thalassemic patients.


Subject(s)
Disease Models, Animal , Iron Overload/etiology , Iron-Dextran Complex/adverse effects , Transfusion Reaction , Animals , Blood Transfusion , Erythropoiesis , Female , Humans , Infusions, Parenteral , Iron Overload/chemically induced , Iron Overload/pathology , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/analysis , Swine , Swine, Miniature
5.
J Pediatr ; 222: 98-105.e3, 2020 07.
Article in English | MEDLINE | ID: mdl-32418819

ABSTRACT

OBJECTIVE: To assess the effects of protocolized recombinant human erythropoietin (r-HuEPO) therapy and standardized high dose iron supplementation on hematologic and iron status measures in a cohort of extremely low gestational age newborns (ELGANs). STUDY DESIGN: Charts of extremely low gestational age newborns admitted from 2006 to 2016 and who had received r-HuEPO per neonatal intensive care unit protocol were reviewed. The r-HuEPO was started at a dose of 900 IU/kg per week after 7 days of age and continued until 35 weeks postmenstrual age. Oral iron supplementation at 6-12 mg/kg per day was used to maintain a transferrin saturation of >20% during r-HuEPO treatment. Data on demographic features, hematologic and iron panel indices, red blood cell transfusions, and clinical outcomes were collected. Quartile groups were created based on serum ferritin levels at the conclusion of the r-HuEPO treatment and the quartiles were compared. RESULTS: The cohort included 116 infants with mean gestational age 25.8 ± 1.5 weeks and birth weight 793 ± 174.1 g. The r-HuEPO promoted erythropoiesis as indicated by increasing hemoglobin, hematocrit, and reticulocyte count. Serum ferritin decreased over time and was ≤75 ng/mL in 60.2% of infants at the conclusion of r-HuEPO therapy; 87% received packed red blood cell transfusions. Transfusion volume, total iron intake, total iron binding capacity, and transferrin concentration differed among infants in the different serum ferritin quartiles (P < .05). CONCLUSIONS: In extremely low gestational age newborns, r-HuEPO therapy promoted erythropoiesis. Despite a biomarker-based standardized high-dose iron supplementation, the majority of infants had evidence of iron deficiency to a degree that is associated with reduced brain function.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Anemia, Iron-Deficiency/epidemiology , Erythropoietin/therapeutic use , Ferrous Compounds/therapeutic use , Hematinics/administration & dosage , Iron-Dextran Complex/administration & dosage , Anemia, Iron-Deficiency/blood , Drug Therapy, Combination , Female , Humans , Infant, Extremely Premature , Infant, Newborn , Male , Prevalence , Recombinant Proteins/therapeutic use , Retrospective Studies
6.
Expert Rev Hematol ; 13(5): 557-564, 2020 05.
Article in English | MEDLINE | ID: mdl-32129113

ABSTRACT

Objectives: It is hypothesized that the risk of hypersensitivity reactions (HSRs) may be lower with ferric carboxymaltose than iron dextran because of its non-dextran carbohydrate moiety. This study compares the risk of HSRs between iron dextran and ferric carboxymaltose.Methods: This was a retrospective pharmacoepidemiological study with a case-population design covering 2008-2017. Global exposure data were estimated using IQVIA™ sales data. Spontaneously reported HSR data were retrieved from the World Health Organization database (VigiBase™) using different search criteria including: the Standardized MedDRA® Query (SMQ) 'Anaphylactic reaction'; type I-IV HSR terms; narrow terms for anaphylactic/anaphylactoid reactions; and cases with a fatal outcome.Results: Total exposure in 100 mg doses was 117.3 million for iron dextran and 84.2 million for ferric carboxymaltose. The relative risk (with 95% confidence interval) for ferric carboxymaltose versus iron dextran was 4.18 (3.88-4.50) for SMQ Anaphylactic reaction; 12.9 (9.90-16.7) for type I-IV HSRs; 1.72 (1.45-2.04) for anaphylactic/anaphylactoid reactions; and 1.92 (1.24-2.99) for death.Conclusion: The risk of spontaneously reported HSRs was consistently higher with ferric carboxy-maltose than with iron dextran over the period 2008-2017. Thus, this study does not support that dextran-free intravenous irons are associated with fewer HSRs than iron dextran.


Subject(s)
Databases, Factual , Drug Hypersensitivity/epidemiology , Ferric Compounds , Maltose/analogs & derivatives , Female , Ferric Compounds/administration & dosage , Ferric Compounds/adverse effects , Humans , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/adverse effects , Male , Maltose/administration & dosage , Maltose/adverse effects , Retrospective Studies
7.
Biol Trace Elem Res ; 195(1): 117-124, 2020 May.
Article in English | MEDLINE | ID: mdl-31377936

ABSTRACT

The present study was to evaluate the consequences of iron status across oral and parenteral iron administrations in prevention of iron deficiency anemia. A total of 24 one-day-old male neonatal piglets were allocated into three groups given non-iron supplementation (NON), intramuscular iron dextran injection (FeDex), and oral administration of ferrous glycine chelate (FeGly), respectively. At day 8, no significant differences in final body weight, average weight gain, and tissue coefficients were observed among three groups (P > 0.05). Both oral FeGly and FeDex injection significantly increased serum iron, ferritin, hemoglobin, and tissue iron deposition (P < 0.05). However, FeDex-injected supplementation resulted in rapidly rising hepcidin levels and hepatic iron deposition (P < 0.05). In addition, compared to parenteral iron supplementation, greater serum IgA level, SOD, and GSH-Px activities, lower expressions of IL-1ß and TNF-α in the liver, and lower expressions of IL-6 and TNF-α in the spleen were found in oral iron piglets (P < 0.05). According to our results, oral administration of ferrous glycine chelate improved iron homeostasis, and oxidative and immune status in anemic neonatal pigs.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Homeostasis/drug effects , Iron Chelating Agents/pharmacology , Iron-Dextran Complex/pharmacology , Iron/immunology , Administration, Oral , Anemia, Iron-Deficiency/immunology , Animals , Homeostasis/immunology , Infusions, Parenteral , Iron Chelating Agents/administration & dosage , Iron-Dextran Complex/administration & dosage , Male , Oxidative Stress/drug effects , Oxidative Stress/immunology , Swine , Weight Gain/drug effects
8.
Biol Trace Elem Res ; 196(2): 472-480, 2020 Aug.
Article in English | MEDLINE | ID: mdl-31701465

ABSTRACT

Heme is an efficient dietary iron supplement applied in humans and animals to prevent iron deficiency anemia (IDA). We have recently reported that the use of bovine hemoglobin as a dietary source of heme iron efficiently counteracts the development of IDA in young piglets, which is the common problem in pig industry. Here, we used maternal Polish Large White and terminal sire breed (L990) pigs differing in traits for meat production to evaluate the long-term effect of split supplementation with intramuscularly administered small amount of iron dextran and orally given hemoglobin on hematological indices, iron status, growth performance, slaughter traits, and meat quality at the end of fattening. Results of our study show that in pigs of both breeds split supplementation was effective in maintaining physiological values of RBC and blood plasma iron parameters as well as growth performance, carcass parameters, and meat quality traits. Our results prove the effectiveness of split iron supplementation of piglets in a far-reach perspective.


Subject(s)
Erythrocytes/drug effects , Hemoglobins/metabolism , Iron-Dextran Complex/pharmacology , Iron/blood , Meat/analysis , Swine , Administration, Oral , Animals , Body Composition/drug effects , Dietary Supplements , Hemoglobins/administration & dosage , Iron-Dextran Complex/administration & dosage , Male , Poland , Swine/anatomy & histology , Swine/blood , Swine/growth & development , Swine/metabolism , Time Factors , Weight Gain/drug effects
9.
Invest Ophthalmol Vis Sci ; 60(13): 4378-4387, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31634395

ABSTRACT

Purpose: Iron supplementation therapy is used for iron-deficiency anemia but has been associated with macular degeneration in a 43-year-old patient. Iron entry into the neurosensory retina (NSR) can be toxic. It is important to determine conditions under which serum iron might cross the blood retinal barrier (BRB) into the NSR. Herein, an established mouse model of systemic iron overload using high-dose intraperitoneal iron dextran (IP FeDex) was studied. In addition, because the NSR expresses the iron regulatory hormone hepcidin, which could limit iron influx into the NSR, we gave retina-specific hepcidin knockout (RS-HepcKO) mice IP FeDex to test this possibility. Methods: Wild-type (WT) and RS-HepcKO mice were given IP FeDex. In vivo retina imaging was performed. Blood and tissues were analyzed for iron levels. Quantitative PCR was used to measure levels of mRNAs encoding iron regulatory and photoreceptor-specific genes. Ferritin and albumin were localized in the retina by immunofluorescence. Results: IP FeDex in both WT and RS-HepcKO mice induced high levels of iron in the liver, serum, retinal vascular endothelial cells (rVECs), and RPE, but not the NSR. The BRB remained intact. Retinal degeneration did not occur. Conclusions: Following injection of high-dose IP FeDex, iron accumulated in the BRB, but not the NSR. Thus, the BRB can shield the NSR from iron delivered in this manner. This ability is not dependent on NSR hepcidin production.


Subject(s)
Blood-Retinal Barrier/metabolism , Endothelial Cells/metabolism , Iron Overload/metabolism , Iron-Dextran Complex/administration & dosage , Iron/metabolism , Retinal Vessels/metabolism , Albumins/metabolism , Animals , Disease Models, Animal , Ferritins/metabolism , Fluorescent Antibody Technique, Indirect , Hepcidins/pharmacology , Injections, Intraperitoneal , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Transferrin/metabolism
10.
Contrast Media Mol Imaging ; 2019: 7463047, 2019.
Article in English | MEDLINE | ID: mdl-31598113

ABSTRACT

Aim: Iron overload is a life-threatening disorder that can increase the risks of cancer, cardiovascular disease, and liver cirrhosis. There is also a risk of iron overload in patients with chronic kidney disease. In patients with renal failure, iron storage is increased due to inadequate iron utilization associated with decreased erythropoiesis and also to the inflammatory status. To evade the risk of iron overload, an accurate and versatile indicator of body iron storage in patients with iron overload is needed. In this study, we aimed to find useful iron-related parameters that could accurately reflect body iron storage in mice in order to construct a murine model of iron overload. Methods: To select an appropriate indicator of body iron status, a variety of parameters involved in iron metabolism were evaluated. Noninvasively measured parameters were R1, R2, and R2 ∗ derived from magnetic resonance imaging (MRI). Invasively measured parameters included serum hepcidin levels, serum ferritin levels, and liver iron contents. Histopathological analysis was also conducted. Results/Conclusion: Among the several parameters evaluated, the MRI T2 ∗ relaxation time was able to detect iron storage in the liver as sensitively as serum ferritin levels. Moreover, it is expected that using an MRI parameter will allow accurate evaluation of body iron storage in mice over time.


Subject(s)
Iron Overload/diagnostic imaging , Liver/diagnostic imaging , Magnetic Resonance Imaging/statistics & numerical data , Animals , Disease Models, Animal , Ferritins/blood , Hemoglobins/analysis , Hemosiderin/analysis , Hepcidins/blood , Injections, Intraperitoneal , Iron/analysis , Iron Overload/metabolism , Iron Overload/pathology , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/pharmacokinetics , Iron-Dextran Complex/toxicity , Liver/metabolism , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Specific Pathogen-Free Organisms , Time
11.
BMC Pediatr ; 19(1): 314, 2019 09 05.
Article in English | MEDLINE | ID: mdl-31488081

ABSTRACT

INTRODUCTION: Iron deficiency anemia (IDA) is a global public health issue that affect more than 2 billion individuals worldwide. However evidence for optimal management of IDA is lacking. METHODS: To assess the diagnostic criteria and therapeutic modalities for pediatric IDA employed by physicians in a major public healthcare facility in Riyadh, a validated questionnaire including demographic data and patient case-scenarios related to diagnosis and treatment of IDA was employed. Robust regression analysis was used to identify factors associated with overall score of participants. RESULTS: Of the 166 physicians surveyed 147(88.6%) were included in the study. Wide variability was observed in IDA diagnosis and therapy practises. For nutritional IDA, only 15.6% recommended no other laboratory tests in addition to CBC. The majority preferred treatment with ferrous sulfate (77.6%) divided into two doses (57.1%), but the total daily elemental iron doses varied widely from 2 to 6 mg/kg. For intravenous iron, 42.9% recommended iron dextran, 32.7% iron sucrose, and 13.4% would continue oral iron. Of all assessed factors, median score was significantly highest in pediatric hematologists compared with pediatricians, family medicine specialists and GPs; p = 0.007, and those work in tertiary care compared with those in primary care; p = 0.043. However, in multivariate robust regression analysis, overall score was only significantly associated with professional qualification [pediatric hematologist ß = 13.71,95%CI 2.48-24.95, p = 0.017; pediatrician ß = 1.77,95%C (- 6.05-9.59, p = 0.66; family medicine ß = 2.66,95%CI-4.30-9.58, p = 0.45 compared with general practitioner]. CONCLUSION: Wide variations exist among physicians in diagnosis and treatment of pediatric IDA. Intervention programs and national guidelines are urgently needed.


Subject(s)
Anemia, Iron-Deficiency/diagnosis , Anemia, Iron-Deficiency/therapy , Administration, Oral , Adult , Anemia, Iron-Deficiency/blood , Blood Cell Count/statistics & numerical data , Blood Transfusion/statistics & numerical data , Chi-Square Distribution , Clinical Laboratory Techniques/statistics & numerical data , Cross-Sectional Studies , Disease Management , Female , Ferric Oxide, Saccharated/administration & dosage , Ferrous Compounds/administration & dosage , Health Care Surveys/statistics & numerical data , Hematinics/administration & dosage , Hemoglobin A/analysis , Humans , Infant , Injections, Intravenous , Iron/administration & dosage , Iron-Dextran Complex/administration & dosage , Male , Physicians/statistics & numerical data , Regression Analysis , Saudi Arabia , Statistics, Nonparametric
12.
BMC Nephrol ; 20(1): 327, 2019 08 22.
Article in English | MEDLINE | ID: mdl-31438879

ABSTRACT

BACKGROUND: Studies have reported conflicting findings on the infection risk posed by intravenous iron supplementation among hemodialysis (HD) patients. We used a novel study design to assess associations between intravenous iron and infectious diseases. METHODS: Patients initiating HD between 1998 and 2008 were extracted from Taiwan's National Health Insurance Research Database. Their first infectious disease in the period between 1.5 years after dialysis initiation and 2010 was identified and defined as the index date. Through the case-crossover design, the odds of exposure to intravenous iron within the 1-month period immediately preceding the index date (i.e., the case period) were compared with iron exposure in three different matched control periods for the same enrollee, thus possibly reducing some unmeasured confounders. RESULTS: A total of 1410 patients who met our enrollment criteria were extracted from incident HD patients. The odds of intravenous iron exposure during the case period versus total control periods exhibited no significant difference (odds ratio: 1.000, 95% confidence interval: 0.75-1.33). In subgroup analyses, this association remained nonsignificant across patients with diabetes mellitus, heart failure, chronic lung disease, venous catheter for HD, and higher iron load. CONCLUSIONS: We found that intravenous iron supplementation did not increase short-term infection risk among HD patients.


Subject(s)
Bacterial Infections/etiology , Hematinics/adverse effects , Iron/adverse effects , Kidney Failure, Chronic/therapy , Renal Dialysis/adverse effects , Administration, Intravenous , Adult , Aged , Bacterial Infections/microbiology , Cohort Studies , Cross-Over Studies , Databases, Factual/statistics & numerical data , Diabetes Mellitus/epidemiology , Epidemiologic Methods , Female , Ferric Compounds/administration & dosage , Ferric Compounds/adverse effects , Ferric Oxide, Saccharated/administration & dosage , Ferric Oxide, Saccharated/adverse effects , Heart Failure/epidemiology , Hematinics/administration & dosage , Humans , Iron/administration & dosage , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/adverse effects , Kidney Failure, Chronic/epidemiology , Lung Diseases/epidemiology , Male , Middle Aged , Multimorbidity , National Health Programs/statistics & numerical data , Taiwan/epidemiology , Time Factors , Young Adult
13.
Trials ; 20(1): 194, 2019 04 04.
Article in English | MEDLINE | ID: mdl-30947751

ABSTRACT

BACKGROUND: Intravenous (IV) iron is frequently used to treat iron deficiency/anemia in patients who are unable to tolerate oral iron or the oral iron is not sufficient toreplete iron requirements. However, safety concerns regarding the potential increase in oxidative stress and other adverse effects persist and it remains unclear whether all iron preparations are equivalent. Indeed, the comparative risk of adverse events with IV iron preparations has not been extensively assessed. We hypothesize that IV iron leads to changes in oxidative stress, endothelial function, and potential renal damage depending on the iron formulation (related to the generation of "free" or catalytic labile iron) and this may result in more tubular and glomerular injury manifested as increased proteinuria and raised neutrophil gelatinase-associated lipocalin (NGAL) levels in patients with chronic kidney disease (CKD). METHODS: IRON-CKD is a prospective, open-label, explorative, randomized, single-center study designed to compare the safety and efficacy of three parenteral iron preparations: low-molecular-weight iron dextran-Cosmofer, iron sucrose-Venofer, and iron isomaltoside-Monofer. The study includes 40 adults who have established CKD stages 3-5 and serum ferritin (SF) of less than 200 µg/L or transferrin saturation (TS) of less than 20% (or both); they were randomly assigned in a 1:1:1:1 ratio to 200 mg iron dextran, 200 mg iron sucrose, 200 mg iron isomaltoside, or 1000 mg iron isomaltoside. After randomization, participants undergo baseline assessments and then an iron infusion. Each participant is followed up at 2 h, day 1, week 1, and months 1 and 3. At each follow-up visit, patients undergo clinical review, measurement of pulse wave velocity (PWV), blood tests for renal function, and collection of serum/plasma samples for oxidative stress and inflammatory markers. The primary outcomes are measures of oxidative stress, inflammatory markers, and markers of acute renal injury in comparison with baseline measures of each iron preparation and between each of the iron preparations. Secondary objectives include effects on hematinic profiles and hemoglobin concentrations, changes in arterial stiffness, incidence of significant side effects, and change in patients' quality of life. RESULTS: Between October 2015 and April 2018, 521 individuals were identified as potential participants; 216 were contacted, 56 expressed an interest, 49 attended a screening visit, and 40 were confirmed to meet the eligibility criteria and were randomly assigned. The mean age was 58.8 (standard error of the mean 2.2) years, and 23 (58%) were male. All patients were white and English-speaking. The mean SF was 68.8 µg/L, TS was 21.4%, and haemoglobin was 122.6 g/L at randomization for the whole group. The mean estimated glomerular filtration rate was 28.2 mL/min/1.73 m2 the urinary protein/ creatinine ratio was 154.2 mg/mmol, and CRP was 7.5 mg/L. DISCUSSION: IRON-CKD will provide important information on the short-term effects of three preparations of IV iron in CKD patients with biochemical functional or absolute iron deficiency on measures of oxidative stress, inflammation, endothelial function, and renal injury. TRIAL REGISTRATION: European Clinical Trials Database (EudraCT) number 2010-020452-64 .


Subject(s)
Acute Kidney Injury/chemically induced , Anemia, Iron-Deficiency/drug therapy , Disaccharides/administration & dosage , Ferric Compounds/administration & dosage , Ferric Oxide, Saccharated/administration & dosage , Hematinics/adverse effects , Iron-Dextran Complex/administration & dosage , Kidney/drug effects , Oxidative Stress/drug effects , Renal Insufficiency, Chronic/complications , Acute Kidney Injury/blood , Acute Kidney Injury/diagnosis , Acute Kidney Injury/urine , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/complications , Anemia, Iron-Deficiency/diagnosis , Biomarkers/blood , Biomarkers/urine , Disaccharides/adverse effects , England , Female , Ferric Compounds/adverse effects , Ferric Oxide, Saccharated/adverse effects , Hematinics/administration & dosage , Hemoglobins/metabolism , Humans , Inflammation Mediators/blood , Infusions, Intravenous , Iron-Dextran Complex/adverse effects , Kidney/metabolism , Kidney/pathology , Lipocalin-2/urine , Male , Middle Aged , Prospective Studies , Proteinuria/chemically induced , Proteinuria/urine , Randomized Controlled Trials as Topic , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/diagnosis , Time Factors , Treatment Outcome
14.
Perit Dial Int ; 39(2): 192-195, 2019.
Article in English | MEDLINE | ID: mdl-30858290

ABSTRACT

Safety of parenteral iron therapy is critical and has been demonstrated in several studies, but concerns persist on safety. We performed a retrospective single-center study investigating the safety and efficacy of parenteral iron administration using 2 iron preparations-Monofer and Cosmofer (Pharmacosmos A/S, Holbaek, Denmark)-in patients with chronic kidney disease (CKD), on peritoneal dialysis (PD) and non-dialysis. A database of CKD patients receiving intravenous (IV) iron was analyzed. Side effects were recorded during infusion, post-infusion, and after 48 hours. In a population of CKD patients (non-dialysis and PD), IV iron is safe with few major adverse effects for these 2 IV iron preparations studied with similar dosing schedules. These data provide reassurance on the relative short-term safety of IV iron preparations regarding acute infusion-related hypersensitivity reactions.


Subject(s)
Disaccharides/administration & dosage , Ferric Compounds/administration & dosage , Hematinics/administration & dosage , Iron-Dextran Complex/administration & dosage , Peritoneal Dialysis , Renal Insufficiency, Chronic/therapy , Disaccharides/adverse effects , Ferric Compounds/adverse effects , Hematinics/adverse effects , Humans , Infusions, Intravenous , Iron-Dextran Complex/adverse effects , Retrospective Studies , Treatment Outcome
15.
J Matern Fetal Neonatal Med ; 32(3): 398-403, 2019 Feb.
Article in English | MEDLINE | ID: mdl-28901214

ABSTRACT

STUDY OBJECTIVE: To test safety, efficacy, and cost-effectiveness of total dose infusion (TDI) of low molecular weight (LMW) iron dextran for treatment of iron deficiency anemia (IDA) during pregnancy in comparison to oral ferrous fumarate. DESIGN: Prospective interventional randomized controlled trial (RCT). Design classification. Canadian Task Force II3. SETTING: Antenatal clinic and causality unit of a tertiary care referral facility and University Hospital. PATIENTS: A total 66 anemic pregnant women (hemoglobin level between 7-10 g/dl). INTERVENTION: Administration of a LMW iron dextran as a TDI (group A) or Oral iron ferrous fumarate 60 mg elemental iron three times daily (group B) followed by remeasurement of hemoglobin after 4 weeks. MEASURES AND MAIN RESULTS: The main outcome measure was clinical and laboratory improvement of anemia after 4 weeks of starting the therapy. Both groups showed a significant clinical improvement of anemia 4 weeks post-therapy. However, the first improvement of symptoms was significantly faster in group A. Complete blood count (CBC) as well as all iron indices were improved in both groups after 4 weeks of therapy, but were significantly better in group A than B. Side effects in group B were mainly gastrointestinal (GIT) while one case of mild hypersensitivity to TDI and another one case of local reaction at the site of injection were reported in group A. CONCLUSIONS: It is concluded that despite being equally effective in improving both clinical and laboratory evidence of IDA, TDI allows iron restoration with a single dose faster than oral iron therapy with a reasonable safety profile. It is a good example of office one-stop therapy. Nevertheless, noninvasive selfusage at home is a clear advantage of the cheaper oral iron therapy which makes it the first choice for treating IDA in the second and third trimesters of pregnancy in tolerable cases.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Iron-Dextran Complex/administration & dosage , Iron/administration & dosage , Pregnancy Complications, Hematologic/drug therapy , Administration, Oral , Adult , Anemia, Iron-Deficiency/blood , Female , Ferritins/blood , Hemoglobins/analysis , Humans , Infusions, Parenteral , Iron/blood , Pregnancy , Pregnancy Complications, Hematologic/blood , Treatment Outcome , Young Adult
16.
J Matern Fetal Neonatal Med ; 32(13): 2214-2220, 2019 Jul.
Article in English | MEDLINE | ID: mdl-29338568

ABSTRACT

BACKGROUND: Iron deficiency anemia (IDA) is one of the most common medical disorder disturbing pregnancies particularly in low resources countries, and contributes significantly to morbidities and mortalities. Thus, early diagnosis and prompt management of IDA is highly recommended. AIM: To Test the efficacy and safety of oral lactoferrin plus health education provided by a nurse versus total dose infusion (TDI) of low-molecular weight (LMW) iron dextran for treating IDA in the second and third trimester of pregnancy. DESIGN: A prospective interventional, randomized, parallel-group, single-center longitudinal study. SETTING: Woman's Health Assiut University Hospital, Assiut, Egypt, at the outpatient clinic and inpatient unit. It comprised 120 cases divided into two groups as pineapple flavored lactoferrin oral sachets 100 mg twice daily with health education (group A) and TDI of LMW iron dextran (group B). MAIN OUTCOME MEASURES: The primary efficacy parameter was clinical improvement and the amount of increase in hemoglobin concentration by 4 weeks after therapy, secondary outcome measures included measurement of the rest of RBC, and iron indices, the adverse effects related to iron therapy and the patient compliance to the treatment. RESULTS: There was insignificant difference between both groups regarding sociodemographic data, parity and mean gestational age. Both groups showed a significant clinical improvement of anemia 4 weeks post-therapy. There was no statistically significant difference in mean Hb level improvement in both groups after 1 month of therapy. However, mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) improved significantly more in group B than A while iron indices (serum iron and serum ferritin) were significantly more in group A than group B. CONCLUSIONS: Pineapple flavored lactoferrin oral sachets plus health education can be widely used as an alternative to TDI iron dextran supplementation due to clinical as well as laboratory improvement of IDA during pregnancy after 1 month of treatment. Proper health education of the pregnant women with nurse recommendations of balanced diet containing good sources of iron would increase awareness of pregnant women and help eradicate IDA with its serious sequel during pregnancy.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Anti-Infective Agents/administration & dosage , Health Education , Lactoferrin/administration & dosage , Pregnancy Complications, Hematologic/drug therapy , Administration, Intravenous , Administration, Oral , Adult , Anemia, Iron-Deficiency/blood , Female , Hematinics/administration & dosage , Hematinics/adverse effects , Humans , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/adverse effects , Pregnancy , Pregnancy Complications, Hematologic/blood , Prospective Studies , Young Adult
17.
Am J Perinatol ; 36(4): 366-376, 2019 03.
Article in English | MEDLINE | ID: mdl-30121943

ABSTRACT

OBJECTIVE: To perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the benefits of intravenous (IV) iron in pregnancy. STUDY DESIGN: Systematic review was registered with PROSPERO and performed using PRISMA guidelines. PubMed, MEDLINE, Web of Science, ClinicalTrials.gov, Cochrane Library, and Google Scholar were searched. Eleven RCTs, comparing IV to oral iron for treatment of iron-deficiency anemia in pregnancy, were included. Meta-analyses were performed with Stata software (College Station, TX), utilizing random effects model and method of DerSimonian and Laird. Outcomes were assessed by pooled odds ratios (OR) or pooled weighted mean difference (WMD). Sensitivity analyses were performed for heterogeneity. RESULTS: We found that pregnant women receiving IV iron, compared with oral iron, had the following benefits: (1) Achieved target hemoglobin more often, pooled OR 2.66 (95% confidence interval [CI]: 1.71-4.15), p < 0.001; (2) Increased hemoglobin level after 4 weeks, pooled WMD 0.84 g/dL (95% CI: 0.59-1.09), p < 0.001; (3) Decreased adverse reactions, pooled OR 0.35 (95% CI: 0.18-0.67), p = 0.001. Results were unchanged following sensitivity analyses. CONCLUSION: In this meta-analysis, IV iron is superior to oral iron for treatment of iron-deficiency anemia in pregnancy. Women receiving IV iron more often achieve desired hemoglobin targets, faster and with fewer side effects.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Iron/administration & dosage , Pregnancy Complications/drug therapy , Administration, Intravenous , Administration, Oral , Anemia, Iron-Deficiency/blood , Female , Ferric Compounds/administration & dosage , Ferric Oxide, Saccharated/administration & dosage , Ferric Oxide, Saccharated/adverse effects , Hemoglobins/analysis , Humans , Iron/adverse effects , Iron-Dextran Complex/administration & dosage , Maltose/administration & dosage , Maltose/analogs & derivatives , Pregnancy
18.
Int J Artif Organs ; 42(6): 318-320, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30556439

ABSTRACT

Anemia is common in patients with mechanical circulatory support and is associated with increased morbidity. Repletion using parenteral iron infusions has been proven to be beneficial in patients with heart failure. In this report, we describe a case of increased power and flows of continuous-flow left ventricular assist device (LVAD) during an iron dextran infusion. We subsequently studied the effects of iron dextran infusion in an in vitro LVAD mock circulatory loop. The observed increase in flow and power was most likely due to drug-patient interaction rather than drug-LVAD interaction. Mock loops and in vivo animal models may be necessary for proactive evaluation of the safety of intravenous (IV) preparations in this patient population.


Subject(s)
Anemia , Heart Failure , Heart-Assist Devices/adverse effects , Iron-Dextran Complex , Thrombosis , Anemia/drug therapy , Anemia/etiology , Blood Coagulation , Female , Heart Failure/blood , Heart Failure/complications , Heart Failure/physiopathology , Heart Failure/therapy , Hematinics/administration & dosage , Hematinics/adverse effects , Hemodynamics , Humans , Infusions, Parenteral/methods , International Normalized Ratio , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/adverse effects , Middle Aged , Thrombosis/blood , Thrombosis/etiology , Thrombosis/prevention & control , Treatment Outcome
19.
Nutrients ; 10(6)2018 Jun 05.
Article in English | MEDLINE | ID: mdl-29874829

ABSTRACT

Early nutrition is key to promoting gut growth and education of the immune system. Although iron deficiency anemia has long been recognized as a serious iron disorder, the effects of iron supplementation on gut development are less clear. Therefore, using suckling piglets as the model for iron deficiency, we assessed the impacts of iron supplementation on hematological status, gut development, and immunity improvement. Piglets were parenterally supplied with iron dextran (FeDex, 60 mg Fe/kg) by intramuscular administration on the third day after birth and slaughtered at the age of two days, five days, 10 days, and 20 days. It was expected that iron supplementation with FeDex improved the iron status with higher levels of serum iron, ferritin, transferrin, and iron loading in the liver by regulating the interaction of hepcidin and ferroportin (FPN). FeDex supplementation increased villus length and crypt depth, attenuated the pathological status of the duodenum, and was beneficial to intestinal mucosa. FeDex also influenced the intestinal immune development by stimulating the cytokines' production of the intestine and enhancing the phagocytotic capacity of monocytes. Overall, the present study suggested that iron supplementation helped promote the development of the intestine by improving its morphology, which maintains its mucosal integrity and enhances the expression of immuno-associated factors.


Subject(s)
Anemia, Iron-Deficiency/prevention & control , Duodenum/drug effects , Intestinal Mucosa/drug effects , Iron-Dextran Complex/administration & dosage , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/immunology , Anemia, Iron-Deficiency/physiopathology , Animal Nutritional Physiological Phenomena , Animals , Animals, Newborn , Cation Transport Proteins/metabolism , Cytokines/immunology , Dietary Supplements , Disease Models, Animal , Duodenum/growth & development , Duodenum/immunology , Duodenum/pathology , Ferritins/blood , Hepcidins/metabolism , Injections, Intramuscular , Intestinal Mucosa/growth & development , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Liver/drug effects , Liver/metabolism , Monocytes/drug effects , Monocytes/immunology , Nutritional Status , Phagocytosis/drug effects , Sus scrofa , Time Factors , Transferrin/metabolism
20.
Parasit Vectors ; 11(1): 206, 2018 03 27.
Article in English | MEDLINE | ID: mdl-29580269

ABSTRACT

BACKGROUND: Cystoisospora suis causes diarrhoeal disease and reduced weight gain in suckling piglets, and a toltrazuril-based oral suspension is available for treatment. Recently a combinatorial product with toltrazuril plus iron has been developed for parenteral application. In this study we compared the efficacy of the injectable product with the oral suspension against experimentally induced piglet cystoisosporosis. METHODS: In a randomised controlled study, three groups of piglets (n = 10-13) were treated either with a fixed dose of 45 mg toltrazuril + 200 mg gleptoferron i.m. per piglet (Forceris®) on the second day of life (study day 2; SD 2) or with 20 mg toltrazuril/kg body weight as an oral suspension (Baycox® 5%) on SD 4 or left untreated (Control group). The Baycox® and the Control group received 200 mg of iron dextran/piglet on SD 2. All piglets were infected with 1000 sporulated C. suis oocysts on SD 3. Faecal samples were taken daily from SD 7 to SD 20 to determine faecal consistency, oocyst shedding and other diarrhoeal pathogens. Body weight was recorded on SD 1 and then weekly until SD 29. Animals were observed daily for general health and after treatment for possible adverse events. RESULTS: In the Control group all animals shed oocysts for 3.1 days on average and all animals showed diarrhoea for an average of five days. Excretion peaked on SD 9 (max. 48,618 oocysts per gram of faeces). Treatment with Forceris® completely suppressed oocyst excretion. In the Baycox® group, low levels of excretion could be detected. Diarrhoea was reduced to single piglets in the treated groups. Body weight development was reduced in the Control group compared to the treated groups. Enteropathogenic bacteria (Escherichia coli, Clostridium perfringens) could be detected. All parameters related to oocyst excretion, faecal consistency and weight gain were significantly improved in the treated groups compared to the Control group without significant differences between the treated groups. Both products were safe to use. CONCLUSIONS: Treatment with both the injectable (Forceris®) and the oral (Baycox®) formulation of toltrazuril in the prepatent period were safe and highly effective against experimental infection with C. suis in newborn piglets.


Subject(s)
Coccidiosis/veterinary , Coccidiostats/administration & dosage , Iron-Dextran Complex/administration & dosage , Sarcocystidae/drug effects , Swine Diseases/drug therapy , Triazines/administration & dosage , Administration, Intravenous , Administration, Oral , Animals , Animals, Newborn , Body Weight , Coccidiosis/drug therapy , Coccidiosis/pathology , Diarrhea/drug therapy , Diarrhea/pathology , Diarrhea/veterinary , Drug-Related Side Effects and Adverse Reactions/epidemiology , Sarcocystidae/isolation & purification , Swine , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...